13Oct 2023
Study Shows Intravitreal  Brolucizumab and Aflibercept Equally Effective for Treatment-Naive Central Involved Diabetic Macular Edema

Study Shows Intravitreal Brolucizumab and Aflibercept Equally Effective for Treatment-Naive Central Involved Diabetic Macular Edema

A recent study evaluating the management of central-involved diabetic macular edema (CIDME) showcased the effectiveness and safety of intravitreal brolucizumab (IVB) and intravitreal aflibercept (IVA) injections in treatment-naive patients. In a cohort of 45 eyes, both groups exhibited significant improvements in visual acuity and reduced central foveal thickness (CFT) after a 12-month follow-up. Notably, both treatments were equally effective in vision improvement and CFT reduction. However, the IVB group required fewer intravitreal injections, suggesting a potential advantage in minimizing injection frequency for CIDME patients, thereby reducing the treatment burden. No ocular complications were reported in either group, indicating the safety of both IVB and IVA treatments.

  • #ophthalmology

Like

Save

Share